Scarica l'app Stockscreener
29.19
2.37%
-0.71
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Enterprise value to revenue forward of Zymeworks Inc. – SWB:ZA8 - TradingView
Zymeworks (ZYME) Session Brief: Climbs 2.69% to $25.99 in the Latest Session; Reference Levels: $24.69 and $27.29 Define the Nearby Reference Levels at the ClosePCR Spike - vinanet.vn
How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story - simplywall.st
ZYME Q2 2026 Earnings: Wider-than-Expected Loss of -$0.62 per Share Reflects Clinical-Stage InvestmentProduct Revenue Analysis - vinanet.vn
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance Australia
Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright - MarketBeat
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - Yahoo Finance
HC Wainwright Issues Negative Outlook for Zymeworks Earnings - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - Macau Business
Zymeworks Inc. to Participate in Upcoming Investor Conferences in September - Quiver Quantitative
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TradingView
Theravance's Once-Daily COPD Treatment Posts $70.7M Sales - Stock Titan
Zymeworks (ZYME) Is Up 7.3% After Q2 Swing Back to Net LossesWhat's Changed - simplywall.st
Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zymeworks (ZYME) Stock Rich Valuation Meets Widening Losses - Sahm
Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
What is HC Wainwright's Forecast for Zymeworks Q2 Earnings? - MarketBeat
Zymeworks Inc. (ZYME): Analyst Consensus and Potential 72% Upside Make This Biotech Stock Worth Watching - DirectorsTalk Interviews
Is Zymeworks Inc (ZYME) Facing Challenges After Q2 Earnings Miss? GF Score: 65/100, Revenue at $4.6M - GuruFocus
Zymeworks Inc. Stock 12‑Month Price Target Raised to $40, Implies 73% Upside - TradingView
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Zymeworks Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Zymeworks Inc. Q2 2026: Revenue $4.6M, EPS $(0.62) — 10-Q Summary - TradingView
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Zymeworks Inc. (NASDAQ: ZYME) details $250M royalty deal and Theravance bid - Stock Titan
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on May 14, 2026. - marketscreener.com
Zymeworks under pressure as earnings arrive amid acquisition By Investing.com - Investing.com Nigeria
What is HC Wainwright's Estimate for Zymeworks Q3 Earnings? - MarketBeat
Segall Bryant & Hamill LLC Takes Position in Zymeworks Inc. $ZYME - marketbeat.com
Earnings Flash (ZYME) Zymeworks Inc. Reports Q2 Revenue $4.6M - marketscreener.com
Zymeworks Inc. to Pursue Additional Strategic Acquisitions - marketscreener.com
A Post Acquisition Look At Zymeworks (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Inc. expected to post a loss of 46 cents a shareEarnings Preview - TradingView
ZYME|Zymeworks Inc|Price:22.598|Chg%:+0.787 - TradingKey
Perceptive Advisors LLC Increases Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks (ZYME) Slips 3.4% to $21.94 as Biotech Sector Faces Renewed VolatilityPut Flow Alert - vinanet.vn
Zymeworks (ZYME) Slides 3.4% to $21.94 as Support Level Comes into FocusIntraday Profile - Vinanet
Zymeworks Inc. Revenue Breakdown – NASDAQ:ZYME - TradingView
Zymeworks Inc. (ZYME) - DirectorsTalk Interviews
Rubric Capital Management LP Acquires 1,250,000 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zymeworks Inc (ZYME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SummitTX Capital L.P. Purchases 97,159 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zymeworks Inc (ZYME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zymeworks Inc (ZYME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zymeworks Inc (ZYME) Balance Sheet - tradingkey.com
Zymeworks Inc (ZYME) Cash Flow - TradingKey
Zymeworks (ZYME) Edges Lower as Shares Test Key SupportOverbought Signal Alerts - vinanet.vn
TradingKey - TradingKey
Zymeworks Inc. Revenue Breakdown – LSX:A3DSSN - TradingView
Zymeworks Inc. (ZYME) Stock Analysis: A 70% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Zymeworks (ZYME) Edges Lower as Stock Consolidates Between Support and Resistance LevelsMomentum Factor - vinanet.vn
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm
Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade
Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):